Journal ArticleDOI
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Reads0
Chats0
TLDR
An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.Abstract:
To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.read more
Citations
More filters
Journal ArticleDOI
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F. Martin,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Stuart L. Fine,Glenn J. Jaffe +5 more
TL;DR: Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.
Journal ArticleDOI
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Robert L. Avery,Dante J. Pieramici,Melvin Rabena,Alessandro A. Castellarin,Ma'an A. Nasir,Matthew J. Giust +5 more
TL;DR: Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and associated with improvement in VA, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, the majority of whom had previous treatment with photodynamic therapy and/or pegaptanib.
Journal ArticleDOI
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
TL;DR: Assessing long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration patients found one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes.
Journal ArticleDOI
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
TL;DR: Ranibizumab represents a novel therapy that, for the first time, appears to have the potential to enable many AMD patients to obtain a meaningful and sustained gain of vision.
Journal ArticleDOI
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Robert L. Avery,Joel Pearlman,Dante J. Pieramici,Melvin Rabena,Alessandro A. Castellarin,Ma'an A. Nasir,Matthew J. Giust,Robert T. Wendel,Arun Patel +8 more
TL;DR: Short-term results suggest that intravitreal bevacizumab is well tolerated and associated with a rapid regression of retinal and iris neovascularization secondary to PDR, and lower doses may achieve a therapeutic result with less risk of systemic side effects.
References
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Vascular endothelial growth factor: basic science and clinical progress.
TL;DR: Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models and is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.
Journal ArticleDOI
Pegaptanib for Neovascular Age-Related Macular Degeneration
TL;DR: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.
Journal ArticleDOI
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Yongmei Chen,Christian Wiesmann,Germaine Fuh,Bing Li,H.W. Christinger,P. Mckay,A.M. de Vos,Henry B. Lowman +7 more
TL;DR: The final antibody has improved affinity for several VEGF variants as compared with the parental antibody; however, some contact residues on V EGF differ in their contribution to the energetics of Fab binding.
Journal ArticleDOI
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical Study
TL;DR: Overall, bevacizumab therapy was well tolerated, with an improvement in VA, OCT, and angiographic outcomes, and although these preliminary results are promising, a randomized controlled clinical trial is necessary before concluding that systemic bevicizumAB therapy is safe and effective for patients with neovascular AMD.